QCI Interpret for Oncology interprets a cancer patient’s genetic data, building a personalized report that informs the oncologist of which genetic mutations are likely causing the cancer, which precision therapies are known to work against these mutations, and where the patient can go to access these treatments or trials.
Munich Leukemia Laboratory, one of the world’s largest leukemia laboratories, has selected QCI Interpret for Oncology to support the analysis, interpretation, and reporting of Illumina’s TruSight Oncology 500 Assay, a comprehensive genomic profiling test for solid tumors.
Learn more about QIAGEN's QIAseq Multimodal Panels for comprehensive genomic profiling of solid tumors and hematological malignancies.
